Novartis beats estimates, impresses in third quarter
This article was originally published in Scrip
Executive Summary
Novartis has posted a better-than-expected set of 3Q earnings: sales grew by 4% to $14.7bn while earnings per share (EPS) jumped by 10% to $1.37. Analysts had anticipated a strong quarter but consensus estimates put growth flat at $14.34bn with EPS of around $1.29, compared with the same period in 2013 (scripintelligence.com, 23 October 2014).